HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.

*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.

<br />

|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>

|-

!Prior Notes (4th Edition)

|-

|

----<br />

|

|FQR has emailed SR several times, last 4/20/22

|-

|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING

|

|

|-

|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING

|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]

|Disease

|

|

|Jennelle Hodge (JH)/ Malini Sathanoori (MS)

|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]

|Disease

|

|

|JH_MS

|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]

|Disease

|

|

|JH_MS

|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]

|Disease

|

|

|

|JH_MS

|

|-

|

|

|

|JH_MS

|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]

|Disease

|

|

|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]

|Disease

|

|

|JH_MS

|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]

|Disease

|

|

|JH_MS

|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]

|Disease

|12/20/23

|

|

|JH_MS

|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]

|Disease

|

|

|JH_MS

|

|Acute Myeloid Leukemia (AML) with Mutated NPM1

|Xinjie Xu, PhD, FACMG

|Complete

|

|-

|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]

|Disease

|

|

|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]

|Disease

|

|

|JH_MS

|

|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes

|Fei Yang, MD, FACMG  <br> Oregon Health & Science University

|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]

|Disease

|

|

|JH_MS

|

|Acute Myeloid Leukemia (AML) with Minimal Differentiation

|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine

|

|

|-

|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]

|Disease

|

|

|

|JH_MS

|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]

|Disease

|

|

|

|JH_MS

|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]

|Disease

|

|

|JH_MS

|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]

|Disease

|

|

|JH_MS

|

|Acute Myelomonocytic Leukemia

|Fei Yang, MD, FACMG <br> Oregon Health & Science University

|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]

|Disease

|

|

|JH_MS

|

|Acute Monoblastic and Monocytic Leukemia

|Fei Yang, MD, FACMG <br> Oregon Health & Science University

|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]

|Disease

|

|

|JH_MS

|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]

|Disease

|

|

|JH_MS

|

|Acute Megakaryoblastic Leukemia (AMKL)

|Fei Yang, MD, FACMG <br> Oregon Health & Science University

|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]

|Disease

|

|

|JH_MS

|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]

|Disease

|

|

|JH_MS

|

|Check reference format

|-

|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]

|Disease

|

|

|JH_MS

|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]

|Disease

|

|

|JH_MS

|

|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome

|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO

|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]

|Disease

|

|

|FQR

|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]

|Disease

|

|

|FQR

|

|

|-

|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]

|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]

|Disease

|

|

|

|

|JH_MS

|

|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified

|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine

|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]

|Disease

|

|

|JH_MS

|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]

|Disease

|

|

|JH_MS

|Check reference format

|-

|

----<br />

|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]

|Disease

|

|GC

|

|Previously within myeloid section under JH/MS editors

|-

|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]

|Disease

|

|

|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland

|Complete

|Date completed by author: 04/28/2022

|-

|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]

|Disease

|

|

|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland

|Complete

|Date completed by author: 04/28/2022

|-

|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]

|Disease

|

|GC

|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]

|Disease

|

|GC

|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]

|Disease

|

|GC

|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]

|Disease

|

|GC

|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]

|Disease

|

|

|Complete

|10/01/2021

|-

|

----<br />

|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]

|Disease

|

|GC

|[[HAEM5:IgG4-related disease|IgG4-related disease]]

|Disease

|

|GC

|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]

|Disease

|

|

|Sudha Arumugam, MD

|Complete

|Date completed by author: 01/24/2022

|-

|

|

|-

|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]

|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]

|Disease

|

|

|HD

|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]

|Disease

|

|

|HD

|NEW (No Prior)

|NEW (No Prior)

|-

|RESOLVE 4th edition ALL-Related NON-WHO entities content

|-

|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty

| ||

|Monoclonal B-cell Lymphocytosis

|

|-

|Hairy Cell Leukemia

|Snehal Patel, MD, PhD

|

|-

|Splenic Marginal Zone Lymphoma

|Snehal Patel, MD, PhD

|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]

|Disease

|

|

|

|

|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]

|Disease

|

|

|

|

|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]

|Disease

|

|

|

|

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|-

|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]

|Disease

|

|

|

|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]

|Disease

|

|

|Rachel D. Burnside, PhD, MBA, FACMGG

|7/28/2023

|Pending

|

|Rachel D. Burnside, PhD, MBA, FACMGG

|7/28/2023

|Pending

|

|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]

|Disease

|

|

|

|Rachel D. Burnside, PhD, MBA, FACMGG

|7/28/2023

|Pending

|

|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]

|Disease

|

|

|

|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]

|Disease

|

|

|PENDING

|

|

|

|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]

|Disease

|

|

|

|

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|-

|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]

|Disease

|

|

|

|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|-

| || || || ||GC|| ||

|Diffuse Large B-cell Lymphoma, Not Otherwise Specified

|NEW (No Prior)

|-

|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

|Kate Berry, MBBS, BBus (Hons), Pathology Queensland

|

|-

| || || || ||GC|| ||

|ALK-Positive Large B-cell Lymphoma

|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)

|

|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23

|-

| || || || ||GC|| ||

|Large B-cell Lymphoma with IRF4 Rearrangement

|Afia Hasnain, MBBS, PhD

|Complete

|

|-

| || || || ||GC|| ||

|Burkitt-Like Lymphoma with 11q Aberration

|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina

|

|-

|NEW (No Prior)

|-

|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|-

| || || || ||GC|| ||

|Plasmablastic Lymphoma

|

|-

|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS

|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital

|NEW (No Prior)

|-

|Intravascular Large B-cell Lymphoma

|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy

|NEW (No Prior)

|-

| || || || ||GC|| ||

|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)

|Aiko Otsubo, PhD, Indiana University, Holli Drendel

|Complete

|

|-

| || || || ||GC|| ||

|Burkitt Lymphoma

|Becky Leung, MBBS (Hons), BSc, Pathology Queensland

|Complete

|

|-

|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||

|

|-

|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma

|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma

|

|-

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|NEW (No Prior)

|-

|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]

|NEW (No Prior)

|-

| || || || ||SG

| ||

|

|-

| || || || ||SG

| ||

|NEW (No Prior)

|-

| || || || ||SG

| ||

|NEW (No Prior)

|-

| || || ||

|SG

|NEW (No Prior)

|-

| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page

|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants

|-

|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING

|SG

| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content

|Prior Notes (4th Edition)

|-

|

----<br />

|NEW (No Prior)

|-

|6/30/24

|Pending

|

|

|-

|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)

|-

|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD

|NEW (No Prior)

|NEW (No Prior)

|3/19/2024

|6/30/24

|Hepatosplenic T-cell Lymphoma

|Michelle Don, MD, MS

|1/21/2021

|

|-

|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)

|NEW (No Prior)

|NEW (No Prior)

|-

|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||

|

|-

|

----<br />

|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]

|Disease

|

|

|NEW (No Prior)

|NEW (No Prior)

|-

|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]

|NEW (No Prior)

|-

|

----<br />